New hope for Tough-to-Treat gut cancers
NCT ID NCT06065371
Summary
This early-stage study is testing the safety of a new two-drug combination for people with advanced gastrointestinal cancers (like stomach, colon, or pancreatic cancer) that have continued to grow despite standard treatments. The trial will enroll about 20 patients to find the best dose and see if the treatment is tolerable. Researchers will also check if a specific marker in the tumor (called Trop-2) can help predict who might benefit most.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henry Ford Cancer-Detroit
RECRUITINGDetroit, Michigan, 48201, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.